Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

Market Cap	3.30B
Revenue (ttm)	673.76M
Net Income (ttm)	-66.73M
Shares Out	130.89M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	0.13 (0.52%)
Ex-Dividend Date	Jan 9, 2025

Volume	1,234,262
Average Volume	3,505,006
Open	24.56
Previous Close	24.78
Day's Range	24.56 - 25.27
52-Week Range	19.00 - 32.78
Beta	0.25
RSI	45.87
Earnings Date	Aug 27, 2025

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,309
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300683

Financial Performance

In 2024, SHE:300683's revenue was 648.97 million, an increase of 7.75% compared to the previous year's 602.28 million. Losses were -69.35 million, -42.60% less than in 2023.